ArticleAntimicrobial agents and chemotherapy2018
Selection and Characterization of Rupintrivir-Resistant Norwalk Virus Replicon Cells
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Recent insights into reverse genetics of norovirus.Virus research · 2023Review
- Norovirus Protease Structure and Antivirals Development.Viruses · 2021Review
- A Novel Class of Norovirus Inhibitors Targeting the Viral Protease with Potent Antiviral Activity In Vitro and In Vivo.Viruses · 2021Article
- Structure-Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections.Microorganisms · 2021Article
- Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections.Microorganisms · 2021Review
- Viral Interference as a Factor of False-Negative in the Infectious Adenovirus Detection Using Integrated Cell Culture-PCR with a BGM Cell Line.Food and environmental virology · 2021Article
- Design, development, and validation of a strand-specific RT-qPCR assay for GI and GII human Noroviruses.Wellcome open research · 2021Article
- A new antiviral scaffold for human norovirus identified with computer-aided approaches on the viral polymerase.Scientific reports · 2019Article
- Noroviruses subvert the core stress granule component G3BP1 to promote viral VPg-dependent translation.eLife · 2019Article
- The Adenosine Analogue NITD008 has Potent Antiviral Activity against Human and Animal Caliciviruses.Viruses · 2019Article
- Norovirus antivirals: Where are we now?Medicinal research reviews · 2019Review
- Human Norovirus: Experimental Models of Infection.Viruses · 2019Review
- Assessment of the anti-norovirus activity in cell culture using the mouse norovirus: Early mechanistic studies.Antiviral chemistry & chemotherapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Human norovirus (HuNoV) is a major cause of nonbacterial gastroenteritis worldwide, yet despite its impact on society, vaccines and antivirals are currently lacking. A HuNoV replicon system has been widely applied to the evaluation of antiviral compounds and has thus accelerated the process of drug discovery against HuNoV infection. Rupintrivir, an irreversible inhibitor of the human rhinovirus 3C protease, has been reported to inhibit the replication of the Norwalk virus replicon via the inhibition of the norovirus protease. Here we report, for the first time, the generation of rupintrivir-resistant human Norwalk virus replicon cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.